期刊文献+

UPLC-MS/MS法测定人血清中的神经内分泌肿瘤标志物5-羟基吲哚乙酸 被引量:3

Determination of 5-hydroxyindoleacetic acid in serum as neuroendocrine tumor marker by UPLC-MS / MS
原文传递
导出
摘要 目的采用超高效液相色谱串联质谱法测定人血清中5-羟基吲哚乙酸(5-HIAA)的含量。方法采用Waters Acquity UPLC BEH C18色谱柱(50 mm×2.1 mm,1.7μm),流动相为2.5 mmol·L-1乙酸铵水溶液(含0.02%甲酸)-甲醇(68∶32),流速0.2 m L·min-1,进样量3μL,柱温35℃,样品室温度6℃;采用电喷雾正离子模式电离,5-HIAA和甲氨蝶呤内标的监测离子分别为m/z 192.2→146.0、m/z 455.3→308.2。结果 5-HIAA的线性范围为0.0100~10.02μmol·L-1,平均回收率为92.1%~96.5%,批内、批间RSD均小于15%。结论所用方法的线性范围宽、分析时间短,可用于神经内分泌肿瘤的诊断及进展监测。 OBJECTIVE To establish an Ultrahigh performance liquid chromatographytandem mass spectrometry( UPLC -MS/ MS) method for the determination of 5 - hydroxyindole acetic acid ( 5 - HIAA) in human serum. METHODS The concentrations of 5 -HIAA were analyzed on Waters Acquity UPLC BEH C18 column(50 mmx 2. 1 ram, 1.7 p,m)with mobile phase consisting of 2.5 mmol·L^-1 ammonium acetate(containing 0.02% aqueous formic acid) - methanol(68 : 32) at a flow rate of 0.2 mL· min^-1. The column temperature was 35 ℃. The sample room temperature was set at 6 ℃ and the injection volume was 3 μL. The eleetorspray source and positive ion scan were used. 5 - HIAA and the international standard were monitored at (m/z) 192.2→146.0 and (m/z) 455.3→308.2,respectively. RESULTS The calibration curve of 5 - HIAA was linear over the range of 0.0100 - 10.02 μ mol· L^-1 The mean recoveries were from 92.1% to 96.5% . The intra - day and inter - day RSD were both less than 15%. CONCLUSION The method is sensitive with a wide assay range and short analysis time. It is suitable for the diagnosis and follow - up of neuroendocrine tumors (NETs) patients.
出处 《华西药学杂志》 CAS CSCD 2015年第4期481-483,共3页 West China Journal of Pharmaceutical Sciences
基金 河南省医学科技攻关计划项目(201203134)
关键词 超高效液相色谱串联质谱法 5-羟基吲哚乙酸 神经内分泌肿瘤 肿瘤标志物 血清 诊断 UPLC - MS/MS 5 - hydroxyindole acetic acid Neuroendocrine tumors Tumor marker Serum Diagnosis
  • 相关文献

参考文献2

二级参考文献21

  • 1朱预.中国胰腺内分泌外科50年胰岛细胞肿瘤的50年[J].中华肝胆外科杂志,2006,12(7):433-435. 被引量:11
  • 2Boudreaux JP,Klimstra DS,Hassan MM,Woltering EA,Jen- sen RT,Goldsmith SJ,Nutting C,Bushnell DL,Caplin ME,Yao JC.The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differen- tiated neuroendocrine tumors of the Jejunum, Ileum, Appen- dix, and Cecum. Pancreas . 2010
  • 3G. Rindi,G. Kl?ppel,A. Couvelard,P. Komminoth,M. K?rner,J. M. Lopes,A.-M. McNicol,O. Nilsson,A. Perren,A. Scarpa,J.-Y. Scoazec,B. Wiedenmann.TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system[J].Virchows Archiv.2007(4)
  • 4Guido Rindi,Tiziana D’Adda,Elisabetta Froio,Giovanni Fellegara,Cesare Bordi.Prognostic Factors in Gastrointestinal Endocrine Tumors[J].Endocrine Pathology.2007(3)
  • 5J. P. Esser,E. P. Krenning,J. J. M. Teunissen,P. P. M. Kooij,A. L. H. Gameren,W. H. Bakker,D. J. Kwekkeboom.Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?[J].European Journal of Nuclear Medicine and Molecular Imaging.2006(11)
  • 6G. Rindi,G. Kl?ppel,H. Alhman,M. Caplin,A. Couvelard,W. W. Herder,B. Erikssson,A. Falchetti,M. Falconi,P. Komminoth,M. K?rner,J. M. Lopes,A-M. McNicol,O. Nilsson,A. Perren,A. Scarpa,J-Y. Scoazec,B. Wiedenmann.TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system[J].Virchows Archiv.2006(4)
  • 7D. J. Kwekkeboom,W. H. Bakker,B. L. Kam,J. J. M. Teunissen,P. P. M. Kooij,W. W. de Herder,R. A. Feelders,C. H. J. van Eijck,M. de Jong,A. Srinivasan,J. L. Erion,E. P. Krenning.Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate[J].European Journal of Nuclear Medicine and Molecular Imaging.2003(3)
  • 8David S. Tichansky M.D.,,Burt Cagir M.D.,,Edward Borrazzo M.D.,Allan Topham B.A.,Juan Palazzo M.D.,Eric J. Weaver M.D., Ph.D.,Andrea Lange M.D.,Robert D. Fry M.D.Risk of Second Cancers in Patients with Colorectal Carcinoids[J].Diseases of the Colon & Rectum.2002(1)
  • 9Yao JC,Hoff PM.Molecular targeted therapy for neuroendocrine tumors[].Hematology Oncology Clinics of North America.2007
  • 10Yao JC,Phan A,Hoff PM,Chen HX,Charnsangavej C,Yeung SC,Hess K,Ng C,Abbruzzese JL,Ajani JA.Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b[].Journal of Clinical Oncology.2008

共引文献88

同被引文献36

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部